Search results
18 maj 2022 · This article summarises the most recent recommendations on drug treatment of type 2 diabetes from the NICE guideline. 1 This rapid update focuses on evidence of cardiovascular outcomes, with a full update of the section now under way.
Abstract. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin, and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus (T2DM). SGLT2is can effectively reduce hyperglycemia thus improving glycemic control and they offer some beneficial effects on the cardiovascular (CV ...
With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus.
This updated guideline provides recommendations for the care and management of people with or at risk for diabetes mellitus at every stage, including prevention, diagnosis, and treatment.
622 Therapeutic confirmatory studies should assess the safety and efficacy of the insulin preparation in 623 type 1 and type 2 diabetes. Patients should be treated to glycaemic target taking into account limiting 624 adverse effects, particularly hypoglycaemia.
31 sie 2019 · Guidelines, diabetes mellitus, impaired glucose tolerance, cardiovascular diseases, epidemiology, risk factors, prevention, cardiovascular risk assessment, patient management, pharmacological treatment, revascularization, patient-centred care.
15 lut 2019 · A concise way to evaluate pharmacotherapy options for type 2 diabetes mellitus is to use the five patient-oriented STEPS criteria: safety, tolerability, efficacy, price, and...
